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ABSTRACT 
 
This paper discusses outcome measures suitable for use by physiotherapists working 
with patients with rheumatoid arthritis. The measures have been successfully used in 
clinical practice, audit and research in the area of rheumatology and with other 
chronic diseases. Together, they provide comprehensive measurement of the disease. 
Both objective and patient-reported measures are included. The tools are as follows: 
grip strength, a visual analogue scale to measure pain, a timed walk test, the Arthritis 
Impact Measurement Scale 2, the Schedule for the Evaluation of Individual Quality of 
Life and the Quality of Life Index. The tools have been found to be easy to administer 
and are suitable for clinical use. They provide an effective means of evaluating 
treatment in both short and long term settings, making them ideal measures for a 
chronic disease.  
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INTRODUCTION 
 
Rheumatoid Arthritis (RA) is a chronic, disabling disease that affects 1% of the adult 
Irish population. The number of people affected is similar in the United Kingdom and 
the United States. It is a commonly treated disease in both rheumatology units and 
general outpatient departments. These patients present a challenge to clinicians due to 
the relapsing nature of the disease, with intervention required at any point along the 
acute-chronic continuum. The aims of treatment are long term as well as focusing on 
immediate problems. Outcome measures used with this patient group should focus on 
the multifarious effects of the disease. 
This paper suggests a number of outcome measures, which may be useful for 
physiotherapists working with people with rheumatoid arthritis.  These measures will 
be discussed in relation to their measurement properties and their suitability for use in 
rheumatoid arthritis 
Outcome measures in rheumatoid arthritis – what has been suggested to date? 
Interest in the use of formal outcome measures in RA has developed under the 
auspices of the International League of Associations for Rheumatology (ILAR). 
OMERACT (Outcome measures in Rheumatoid Arthritis Clinical Trials) is a 
gathering of professionals interested in outcome measures in RA
 
(Dequeker 1999). 
Recent work has included the incorporation of toxicity, generic health status and 
economic evaluation as well as outcome measures in osteoarthritis and osteoporosis. 
The output from an OMERACT Conference in 1993 resulted in the designation of 
eight endpoints to be used in research trials in RA (Table 1) (Tugwell and Boers 
1993). Similiarly, the American College of Rheumatology (ACR) (Felson et al 1993) 
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has recommended a core set of outcome measures to be utilised in trials involving 
patients with RA (Table 1). 
These outcome measures are intended for medical trials and would not be entirely 
relevant to physiotherapy practice; indeed their use would perhaps preclude accurate 
measurement of change as a result of physiotherapy intervention. They are mentioned 
here because a number of themes emerge on analysis of the recommendations, namely 
that one measure may not be sufficient, the requirement for measurement within the 
context of the International Classification of Functioning, Disability and Health (ICF) 
(see below) levels and the incorporation of patient reported measures.  
The WHO has agreed on a new classification system, the International Classification 
of Functioning, Disability and Health, the ICF (WHO 2001). The overall aim of this 
new classification is to provide a unified and standard language and framework for 
the description of health and health-related states. The new system defines health in 
two parts a) Functioning and Disability, and b) Contextual Factors.  
Functioning and Disability is composed of two components: a) Body Functions and 
Structures and b) Activities and Participation, while the second part, Contextual 
Factors, contains two elements: Environment and Personal factors.  
The outcome measures presented here will be mentioned also with respect to the 
definitions incorporated in the new classification. 
Outcome Measures for Use in Current Research 
 As part of ongoing and previous (Kennedy et al 2001) research into the clinical and 
cost-effectiveness of in-patient and out-patient rehabilitation for patients with RA in 
Ireland, the authors employed and evaluated a variety of outcome measures 
considered to be appropriate for use in physiotherapy departments that are attended by 
patients with RA. Given the constraints of time in the clinical setting, the feedback 
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from patients, and the measurement properties of the measures, we suggest the 
following: 
1. Visual Analogue Scale to measure Pain intensity  
2. Grip strength using a mechanical hand held dynamometer 
3. Timed “Up and Go” test  
4. The Arthritis Impact Measurement Scale 2 (AIMS2)
 
 
5. Quality of life may be measured by the Quality of Life index or by using the 
Schedule for the Evaluation of the Individual Quality of Life (SEIQoL). 
We present them, for consideration, as a battery of tests for use by physiotherapists. 
Initially, a brief review of the properties of measurement will be given. Each outcome 
measure will then be discussed within the context of its measurement properties. With 
regard to the ICF classification, pain (WHO, 2001, p68) and grip strength (WHO, 
2001, p96) are components of “Body Structures and Function” whereas the functional 
measures, such as AIMS 2 and the Timed ‘Up & Go’ would comprise descriptors 
included in the “Activities and Participation” component. 
Measurement properties 
To measure something is to quantify it and to determine the extent of it by 
comparison with a standard unit (Wade 1992).  
Selection of an outcome measure should consider the level of measurement and the 
measurement properties of reliability, validity and sensitivity.  Reliability pertains to 
the consistency or repeatability of measurements (Table 2). However, it should be 
noted that not all measurements are equally error free (Rothstein 2001). The critical 
issue is whether the error will affect the use of the measure. Reliability is measured 
using various statistics depending on the level of measurement (see Table 2). General 
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consensus on the acceptable range of reliability is a correlation (r) from 0.65 to 0.94. 
A more discussion of reliability can be found in McDowell and Newell (1996).  
Validity refers to the appropriateness of the measure for the purpose it was intended 
(Table 3) and sensitivity refers to the ability of the measure to detect the relevant 
clinical change.  Evidence of each of these properties should be sought for an 
outcome measure before deciding on its use. Further information on each of these can 
be obtained from Rothstein (2001), Streiner and Norman (1995), Wade (1992) and 
Richman et al (1980). The outcome measures suggested for use with rheumatoid 
arthritis will now be examined with respect to each of these properties. 
For clarity, Table 4 outlines each outcome measure with respect to reliability, validity 
and sensitivity. Only available evidence for each component is listed in the section 
below. 
OUTCOMES FOR USE WITH RHEUMATOID ARTHRITIS 
1. Visual Analogue Scale to measure pain 
Description 
A Visual Analogue Scale is a 100 millimetre straight line used to measure the 
intensity of pain.  The ends of the line define the extreme limits of pain, with the 0mm 
end of the scale represents ‘no pain’, while the 100mm end represents the ‘worst pain 
ever experienced’.  The line can be orientated vertically or horizontally. The test can 
measure pain at one point in time (absolute) or over time (comparative) (Downie et al 
1978, Scott and Huskisson 1976, Dalton and McNaull 1998, Chapman et al 1985, 
Carlsson 1983). 
Scoring 
The measure is scored by counting the number of millimetres from 0mm to the patient 
score. A VAS is easy to administer and appears to be understood by all patients. 
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Attention should be paid to the reproducibility of the line as photocopying can alter 
the length of the line and thus invalidate results. 
Reliability 
a) Inter-rater reliability 
Not applicable as scale is self-reported 
b) Intra-rater reliability 
Not applicable as scale is self-reported 
c) Test-retest 
Dixon and Bird (1981) investigated the ability of subjects to reproduce an existing 
mark on a VAS. While reproducibility was variable, it was noted that the most 
variability was demonstrated +/- 2cm from the midpoint.  
Validity 
a) Content 
In asking a patient to describe the intensity of pain, we are explicitly directing them 
towards a measure of pain; hence there is no doubt about what domain is being 
measured, albeit a one-dimensional component of a multi-dimensional. 
b) Construct 
Pain is difficult to define and is multi-faceted: thus construct validity is hard to 
establish. However, it has been noted that higher scores on other measure of pain are 
linked with higher scores on VAS (Downie et al 1978). 
c) Criterion – related 
 Downie et al (1978) demonstrated good correlation between a numerical rating scale 
(r=0.9), a simple descriptive scale (r=0.78), a vertical VAS (r=0.88) and the 
horizontal VAS.  
Sensitivity 
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The VAS is a sensitive, measure of pain provided that the divisions used on the scale 
are uniform and consist of at least twenty divisions (Scott and Huskisson 1976) 
Completion Time 
This can take up to 5 minutes from explanation of task to completion by the patient 
2. Grip strength 
Grip Strength is most objectively measured using a dynamometer, such as the Jamar 
dynamometer.  
Description 
The Jamar dynamometer is an industry standard in use for over 35 years.  
Techniques to aid in the standardisation of the procedure have been identified and 
listed (Owners Manual for Jamar Dynamometer).
 
 
Reliability 
a) Inter-rater reliability 
This was demonstrated by testing the correlation between two testers for testing of 
both hands. Correlation (r) between the two testers was calculated as 0.99 for testing 
of both hands (Pearson Product Moment Correlation Co-efficient (PPMCC)) 
demonstrating good inter-rater reliability (Mathiowetz, Weber, Volland and Kashman 
1984). 
b) Test-retest reliability 
Again, the correlation of two separate observations of grip strength tests a week or 
less apart was calculated. The correlation (r) was 0.88 for a mean of three tests for the 
right hand and r = 0.92 for the mean of three tests for the left hand, as measured by 
the Pearson correlation coefficient (Mathiowetz, Weber, Volland and Kashman 1984).  
Validity 
a) Content 
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A dynamometer directly measures grip strength therefore the Jamar dynamometer has 
good content validity. 
Evidence of its validity has been established (Mathiowetz, Weber, Volland and 
Kashman 1984). To do this, a number of known weights were hung from the 
dynamometer. Accuracy of measurement for the dynamometer was established to be 
+/- 3%. 
Average Completion times: 
The test takes approximately 5 minutes to complete. 
3. The Timed “Up & Go” test 
This test was developed by Podsiadlo and Richardson (1991) as a modified version of 
the “Get Up & Go” test (Mathias, Nayak and Isaacs 1986).  
Description 
The Timed “Up & Go” test is a quick test of basic mobility. It requires no special 
equipment (except for a rehabilitation chair and a stop-watch); thus it is a simple test 
to perform. 
Although originally designed for use with older patients, it has been used as an 
outcome measure by McMeeken et al (1999) investigating the effect of knee extensor 
and flexor muscle training in individuals with RA. Following specific muscle training 
using an isokinetic dynamometer for 17 patients with RA, faster Timed “Up & Go” 
test times, greater peak speed (from the isokinetic dynamometer), less pain and better 
quality of life were recorded. It has also been used to measure the effects of a period 
of rehabilitation in a rheumatic diseases unit (Kennedy et al 2001). 
A standardised procedure is available for the test (Podsiadlo and Richardson 1991).  
Scoring 
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The time taken to complete the test for each patient is recorded in 
seconds/milliseconds. 
 
Reliability 
a) Inter-rater reliability 
To test the interrater reliability, twenty-two patients were rated by three raters in 
random order at different times in the same day while performing the test. The 
correlation (r) (intraclass correlation coefficient (ICC)) was 0.99, indicating high 
interrater reliability (Podsiadlo and Richardson 1991). As sample size was small here, 
a high correlation would be necessary to demonstrate good reliability. 
b) Intra-rater reliability 
Twenty patients were observed by the same rater on two consecutive visits to the day 
hospital (physiotherapists n =20, physicians n = 10). The correlation (r) (ICC) was 
0.99, again indicating good intra-rater reliability (Podsiadlo and Richardson 1991). 
Again, due to the small sample size, it is necessary to have a high ICC value to 
demonstrate good inter-rater reliability. 
c) Internal Consistency 
 
Not applicable  
Validity  
a) Criterion – related 
Podsiadlo and Richardson (1991) hypothesised that the timed “Up and Go” test would 
correlate to patients balance, walk speed and functional capacity. Thus its relationship 
to the Berg Balance Scale, gait speed and the Barthel Index of Activities of Daily 
Living was established. When compared to the Berg Balance Scale the correlation r  
(Pearson correlation coefficient) was = - 0.72, for Gait Speed  r  = -0.55 and for the 
Barthel Index,  r  = -0.51, indicating good criterion-related validity. 
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Average completion times are under 20 seconds for patients who are independent in 
basic transfers.  
4. Arthritis Impact Measurement Scale 2 (AIMS2) 
The AIMS was developed in 1980 by Meenan (1982). A revised edition, the AIMS2 
was developed in 1992
 
(Meenan et al 1992). This was a more comprehensive and 
sensitive version of the original. 
Description: 
The AIMS2 is a self-administered evaluation instrument to measure patient outcome 
in the rheumatic diseases. It is a 78-item questionnaire containing scales such as 
Mobility Level, Walking and Bending, Hand and Finger Function, Arm Function, 
Self-Care Tasks, Household Tasks, Pain, Social Activity, Level of Tension and Mood. 
Reliability  
a) Inter-rater reliability 
Not applicable as questionnaire is self-report 
b) Test-retest 
A score of r = or > 0.8 for all components of the scale except work (r =0.78) as 
measured by ICC of scores from two administrations of the instrument separated by 
two to three weeks in a sample of 45 patients over a 2 week period was demonstrated 
by Meenan et al (1992).  
c) Internal Consistency  
The reliability of all 12 scales of the questionnaire, as measured by the internal 
consistency (Cronbach’s alpha) of their component items, were r between 0.72 – 0.91 
for the  RA group (n=299), (Meenan et al 1992). 
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Validity 
a)  Content 
This was established by Meenan et al upon development of the questionnaire (1982) 
by giving the questionnaire to 335 rheumatologists to analyse from the point of view 
of clarity and relevance of the chosen items to the arthritis.  
b) Construct 
Meenan (1992) examined the validity of the AIMS2 and demonstrated that when 
patients assigned an area as a problem, then this area was associated with a poorer 
AIMS2 score in that area. Potts and Brandt
 
(1987) provide further evidence of the 
validity of the original scale. The responses of one hundred and twenty patients who 
scored the AIMS were examined to determine if a correlation existed between their 
scores and the importance rating that they apportioned to each section such as pain, 
anxiety, depression, dexterity and physical activity. The results obtained had a 
significance level of p=0.01, providing evidence for the validity of the pain, anxiety, 
depression, dexterity and physical activity subscales of the AIMS. However, the 
authors conceded that the subscale on household activity might not be appropriate for 
male respondents. Finally, Hughes et al (1991)
 
adapted the AIMS for use with frail, 
elderly respondents. Scores were obtained from four hundred and thirty eight elderly 
patients (mean age 76 years). This revised version was interviewer administered. A 
generic and an arthritis specific score were obtained to help identify if a co-morbid 
condition was implicated. Ninety percent of subjects had osteoarthritis, whereas just 
three percent had RA. The authors concluded that due to the chronic, disabling nature 
of RA, the investigator-administered GERI-AIMS may be appropriate in frail, elderly 
patients. 
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c) Criterion – related 
This was not established, as the authors of the questionnaire were unable to locate a 
suitable standard with which it could be compared. 
Sensitivity  
Anderson et al (1989)
 
investigated the sensitivity of the AIMS2 to the short-term 
clinical changes in arthritis. Having analysed data from three clinical trials, substantial 
improvements in physical function, psychological status and pain and overall arthritis 
impact were detected. These changes occurred at initial assessment, at four weeks 
and/or at eight weeks, indicating the sensitivity of the AIMS2 to detect change.  
Meenan et al (1984) also reported that the AIMS was sensitive to clinically 
meaningful drug-induced change in patients with rheumatoid arthritis. 
Average completion times are approximately twenty minutes. 
 
Quality of life 
Information provided by quality of life instruments can be useful in determining 
prognosis
 
(Bell, Bombadier and Tugwell 1990). Measures of quality of life have been 
developed out of a need to define the impact of health care interventions on 
individuals. The choice of quality of life measure depends on whether a disease 
specific or a generic measure is required. Commonly used generic tools include the 
Sickness Impact Profile, the Nottingham Health Questionnaire, the McMaster Health 
Index and the SF-36. It is becoming increasingly common to use both a disease-
specific and a generic measure. 
6. The Schedule for the Evaluation of Individual Quality of Life (SEIQoL) 
 The SEIQoL (O’Boyle 1994) is a quality of life measure that evaluates individual 
quality of life. As each individual’s life experiences are unique, a need exists for 
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individual assessment and rating of personal quality of life. The development of the 
questionnaire was based on a number of basic propositions. Firstly, QoL is individual 
and secondly, that a person’s judgement of their overall QoL is made based on all the 
domains or areas of that person’s life important to them. 
Description 
Patients are ask to name five important cues (areas) in their lives, to rate the current 
status of each cue and their importance relative to each other.  
Scoring 
An index is calculated which can be analysed using parametric statistics. Frequently 
elicited cues include family, relationships, health, finances, living conditions, work, 
social, religious or spiritual life.  
Scores range from 0 –100, with a higher score indicating superior quality of life. 
Reliability  
Evidence for the reliability of the questionnaire could only be found with respect to  
internal reliability. Internal reliability relates to consistency amongst individuals with 
respect to their judgements of their quality of life. Correlation scores r ranged from 
0.49 to 0.74 (O’Boyle 1994). More research is needed to determine the reliability of 
this tool due to the wide range of reliability scores obtained. 
  
Validity  
Evidence for the validity of the questionnaire could only be found with respect to 
internal validity. Internal validity was explained by the author as reflecting the 
proportion of the variance in the overall QoL judgement. This was measured by the 
square of r  (r
2 
) of scores from various studies involving the SEIQoL. Scores ranged 
from 0.62 to 0.79 (O’Boyle 1994). However, more work is necessary to demonstrate 
evidence of construct and criterion referenced validity. 
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Average completion times are 10 to 20 minutes 
 
7. The Quality of Life Index 
This index was developed in 1981 (Spitzer et al 1981). Originally developed for 
cancer patients, it is suitable for use with patients with a chronic physical disease such 
as rheumatoid arthritis.  
Description 
The measure consists of 5 subscales: Activity, Daily Living, Health, Support and 
Outlook. For each heading there are three possible choice answers 
Scoring  
Scores for each question are summed to determine the overall index, ranging from 1 – 
10, with a high score again indicating satisfaction with quality of life. 
Reliability:  
a) Inter rater reliability  
This was assessed by two Canadian physicians who independently assessed 64 
physicians within seven days using the instrument, resulting in an interrater 
correlation coefficient (r) of 0.81 (as measured by Spearmans rank correlation 
coefficent)(Spitzer et al 1981). 
b) Internal consistency  
This was determined by calculating Cronbach’s  to test if the items in the 
questionnaire are similar to the underlying constructs or theories that relate to quality 
of life. The correlation was calculated as r = 0.775, indicating good internal 
consistency (Spitzer et al 1981). 
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Validity:  
a) Content 
A pre set a priori criterion of 51% for each of the two independent panels that 
reviewed the index was set. The first panel consisted of 34 lay people composed of 
healthy people, people with cancer and other chronic diseases and patient’s relatives. 
The second panel, an expert panel, consisted of 34 health professionals and 
methodologists. Each panel had to respond in the affirmative for each question by a 
majority vote (51%).  This was achieved resulting in high content validity (Spitzer et 
al 1981). 
b) Construct 
This was examined by testing a unidimensional scale and a comprehensive 
multidimensional scale as well as the QoL index on a sample of well and sick 
patients. Agreement was strong and statistically significant at 0.005 and 0.001 levels 
for the panel of sick patients (Spitzer et al 1981). A statistically significant result of p 
= 0.005 or 0.001 would provide strong evidence for the construct validity of the tool. 
 
Average completion time: 3 to 5 minutes  
 
DISCUSSION 
While the importance of employing carefully constructed and relevant instruments or 
scales to measure intervention is now well-recognised in rehabilitation, the decision-
making paradigms used by therapists in choosing the outcome measurements are 
often hampered by the fact that studies on the measurement properties are published 
in diverse sources. In addition the relevance of the measurement properties of the 
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instrument are often not grounded clearly in language that is relevant to the 
‘measurer’ and the ‘measured’.  
If a method of measuring outcome is not reliable, it is pointless to employ it, since the 
change in the patients’ score might be due to errors within the measure itself or errors 
on the part of the therapist using it. Inter-rater reliability considers inter-observer 
variability. Hence it relates to the reproducibility of test results obtained between one 
tester and another. In an instrument or scale that is patient-reported, this is not a 
relevant domain to investigate, however, with tests of strength and timed tests, this 
type of reliability is essential. The inter-rater reliability of the methods of measuring 
grip strength (Jamar dynamometer) and speed during a functional task (Timed Up & 
Go) have been investigated, with reported correlation co-efficients of r=0.97 and 
r=0.99 respectively. Similarly the measurements of quality of life, using the Quality 
of Life index will yield consistency between different assessors enhancing the use of 
the index in daily patient management. 
Intra-rater reliability considers the reproducibility of a measure and how it may be 
subject to errors or changes that occur due to a lack of accuracy in repeating the test 
within the individual tester. Test-retest reliability, defined clearly by Feinstein (1987) 
‘requires examination of two different versions of the same index’, however the term 
is often used inter-changeably with intra-rater reliability. The Timed “Up and Go” test 
demonstrates good reliability over different assessments for the same tester, indicating 
its usefulness and stability as a repeated measure to document actual change in 
reported pain. However, the evidence for ‘test-retest’/intra-rater reliability was 
established using just 8 patients: thus further investigation may be warranted to 
ascertain greater accuracy. Strong evidence for this type of reliability is available for 
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grip strength also (r = 0.80) and for the AIMS2 (r = 0.80). Repeated testing of 
different forms of the scales has not been reported. 
A final aspect of reliability is internal consistency - the manner in which the 
different components of a scale relate to each other, how the individual items in a 
multi-dimensional scale form a unit. It is not relevant for uni-dimensional measures. 
A high level of agreement suggests that individual components relate to one another 
in a way that suggests overall contribution to one domain. If the level of agreement is 
too high, one component might be irrelevantly included and should have been omitted 
in its development. Evidence of internal consistency was found for the AIMS2. Thus 
there is high correlation between different divisions of the AIMS2, contributing to its 
usefulness as a measurement tool in arthritis. Both quality of life measures have 
internal consistency (QoL index:  r = 0.775 and the SEIQoL: r = 0.49 to 0.74).  
And so to validity, which is the process of examining the measurement with a view to 
considering its content, the groups to which it may most appropriately pertain and the 
extent of the interpretation that may be applied to its output (McDowell & Newell, 
1986). Criterion validity is concerned with the extent to which a measurement relates 
to the “gold” standard measurement in the area. This is usually the same phenomenon. 
In examining criterion validity, the relationship of the measurement to another, taken 
at the same point in time, refers to concurrent validity and its ability to relate to a 
measure taken in the future refers to its predictive validity. If no ‘gold standard’ exists 
for comparison, and in comparing it with other existing scales or instruments, a 
relationship is noted, this may be referred to as convergent validity. Evidence of this 
is available for the VAS and its correlation to the Verbal Rating Scale (VRS) another 
tool utilised in pain measurement. The VAS correlates well to the VRS (r = 0.70) 
indicating the ability of the VAS to measure pain intensity. The Timed “Up and Go” 
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test has also been correlated to other standards in the area. When correlated with the 
Berg Balance Scale (convergent) the correlation r  was = - 0.72, with gait speed 
(criterion) r  = -0.55 and for the Barthel Index,  r  = -0.51, indicating the various 
components of criterion validity. New measurement tools are born out of a need to 
measure different dimensions of health. To this end, exact correlation with another 
standard tool in the area would not be expected. Correlations of below r = 6.5 can 
thus be acceptable in view of differing needs.  Construct validity is concerned with 
the scores or results obtained using the new measure and underlying theories upon 
which the measure is based. For example, in a sample of people with established gait 
disorders, one might expect a lower score on an instrument measuring gait, than in a 
‘normal’ sample. If this hypothesis is tested and found to be true, construct validity is 
supported. As pain is multi-dimensional, it is difficult to establish construct validity 
for the VAS. No explicit evidence for the construct validity of grip strength or for the 
Timed “Up and Go” test was found to be reported. The evidence for the construct 
validity of the AIMS2 is available, indicating its correlation to its underlying theory 
that health encompasses physical, psychological and social states. Similarly, the QoL 
index was examined for its correlation to its underlying constructs and results were 
found to be significant.  Content validity reflects the adequacy of the tool in reflecting 
the aims outlined in the original definition of the measure. It is often quite apparent 
from the scale, but can be supported by user consensus, often carried out as part of the 
preliminary development process. The VAS demonstrates content validity since it 
measures self-reported pain, for which it was intended. Similarly, the Jamar 
dynamometer measures grip strength accurately, allowing for its suitability to the 
clinical setting. Grip strength is frequently decreased in the rheumatoid patient, 
resulting in decreased hand function. Thus its inclusion in assessing the outcome of 
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treatment allows for accurate measurement of intervention and the displaying of any 
resulting improvement.  
Evidence of the content validity of the Timed “Up and Go” test was not found. It 
clearly examines a timed task involving two functional activities – gait speed and sit 
to stand and as such is a suitable inclusion in the measurement of any disease 
resulting in impaired lower limb function. The AIMS2 also has content validity as it 
contains various items relevant to the arthritic patient such as pain, mobility, hand 
function, walking and bending as well as social activities and anxiety and depression. 
All of these areas, and more, can be affected in the patient with a rheumatic disease. 
Similarly, the QoL index displays content validity by measuring the various aspects of 
quality of life relevant to patients with a chronic disease such as activity, daily living, 
health, support and outlook. 
The final property of a measurement tool is sensitivity, which refers to the 
ability of the tool to detect relevant clinical change. This is important in the clinical 
setting, as certain outcomes of treatment may indeed be small but relevant if they 
produce improved function.  Liang et al (1995) suggest that it is this measurement 
property that is least well studied. This is consistent with the information we present 
in this paper.  The AIMS2 is documented as a sensitive tool and has shown that it can 
reflect changes following intervention that may be relevant to the rheumatoid patient. 
All of the methods of measuring outcome described in this paper have been 
successfully employed in clinical research, as part of an audit of clinical practice in a 
rheumatology unit
 
(Kennedy et al 2001) and are employed in an ongoing research 
trial. While the measures have been described separately, their interrelationship has 
also been previously considered and yielded results that support the inclusion of an 
eclectic battery of tools to measure outcome in Rheumatoid Arthritis. The relevance 
 21 
of the measurement properties to each outcome measure and to the clinical setting 
will now be discussed. Pain, grip strength and walking time have all demonstrated a 
relationship to self-reported functional ability (Spiegel et al, 1987; Ward and Leigh, 
1993, Vliet Vlieland et al, 1996; Nordenskiold and Grimby, 1997) but they have not 
shown the ability to relate to disease markers such as Erythrocyte Sedimentation Rate 
and C-Reactive Protein. Borstlap et al (1993)
 
investigated the overlap between clinical 
and laboratory tests and a Dutch quality of life measure. Results indicated that 
laboratory and clinical measures (Erythrocyte Sedimentation Rate, C-Reactive 
Protein, grip strength and functional classification) were significantly correlated 
(p<0.001) with physical dimensions of the quality of life measure. van der Heide et al
 
(1993) noted that self-reported measures of physical ability reflect current disease 
activity whereas the number of assistive devices/aids used reflects disease duration, 
and suggest the importance of differentiating between difficulty in performance and 
duration of disease. 
Advantages associated with these suggested measures include their low cost, 
sensitivity, ease of administration, evidence of validity and reliability for each 
measure and the existence of established inter-relationships. The SEIQoL usually 
takes between 5 and 15 minutes to complete. This may limit its use in the clinical 
setting due to time constraints. It does allow for exploration of individual issues with 
patients and may allow for the consideration of cognitive issues such as coping 
strategies and perceptions of how illness impacts on a range of aspects pertinent to 
particularities of specific patients. Scharloo et al
 
(1999) note that after controlling for 
disease duration and severity, these issues are relevant to health outcomes in RA.  
Due to the frequent involvement of the finger joints and wrists in the disease, hand 
function is affected in patients with RA. The undertaking of everyday tasks can be 
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severely limited. Dressing, feeding and other self-care tasks are negatively affected. 
The impingement on hand function can be assessed by measuring grip strength and by 
using hand function tests such as the Jebsen Taylor Hand Function test
  
(Jebsen et al, 
1969). However, with regard to clinical assessment, grip strength may be more 
acceptable measure to physiotherapists, as many hand function tests can be time 
consuming and in addition are often completed by the occupational therapy 
department, which would thus duplicate assessments.  
 
CONCLUSION 
The use of outcome measures is imperative to determine the effectiveness of 
treatment. This is particularly relevant with a chronic disease such as rheumatoid 
arthritis. The outcome measures presented here have been found to be valid and 
reliable and suitable for use in clinical and research settings. By measuring at the 
levels of impairment, disability and handicap they provide a comprehensive 
assessment of the disease process and allow for the accurate evaluation of 
intervention. 
KEY POINTS 
1. The use of outcome measures is necessary to determine clinical effectiveness 
2. Outcome measures used should aim to evaluate within the context of the 
International Classification of Functioning, Disability and Health (ICF)  
3. A comprehensive range of outcome measures are presented which encompass 
all aspects of a chronic disease such as rheumatoid arthritis 
4. These measures can be routinely incorporated into routine clinical practice 
5. Use of these outcome measures can facilitate accurate evaluation of treatment 
for rheumatoid arthritis 
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Table 1: Outcome measures in Rheumatoid Arthritis Clinical Trials 
(OMERACT) and American College of Rheumatology (ACR) recommendations 
for outcome measures in Rheumatoid Arthritis trials 
 
OMERACT ACR 
Acute Phase Reactants One  Acute Phase Reactant 
Tender joint count Tender joint count 
Swollen joint count Swollen joint count 
Pain Patient’s assessment of pain 
Patient global assessment Patient’s global assessment of disease 
activity 
Physician global assessment Physician’s global assessment of disease 
activity 
Disability Patient’s assessment of physical function 
Radiographic studies of joints (for studies 
of one year or longer) 
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Table 2: Reliability – description of each type 
 
 
* Test –retest and intra-rater reliability both refer to the repeatability of a measure 
over time. The reliability quoted by a test developer or analyser should be interpreted 
according to the method used to calculate it, that is does the method refer to the tester 
(intra-rater) or to the test (test-retest). 
 
 
 
 
 
 
 
 
Type Inter-rater Intra-rater Internal 
Consistency 
Test-retest 
Description The degree of 
agreement 
between different 
raters using the 
same test 
The degree of 
agreement 
between one rater 
for each repetition 
of the same test 
The overall 
consistency of the 
measure among 
the different items 
of a multiple 
response 
instrument 
Repeatability of 
measures over 
time* 
Measurement 
Method 
Intraclass 
correlation (ICC) 
(for ratio scales) 
or less commonly, 
Pearson 
correlation 
coefficient and 
Spearman rank 
correlation 
coeffficent 
 Cronbach’s 
coefficient alpha 
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Table 3: Types of Validity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type Content Construct Criterion 
Description The adequacy of 
the sampling 
questions in 
reflecting the aims 
of the index that 
were specified in 
the conceptual 
definition of its 
scope (McDowell 
and Newell)  
The degree to 
which the 
scores 
obtained 
concur with 
the underlying 
theories 
related to the 
content of the 
measure. 
It can be 
divided into 
Convergent 
and 
Discriminant  
The extent to 
which the 
measure 
concurs with 
“gold-
standards” in 
the same area. 
It can be of 
two types 
Predicitive 
and 
Concurrent 
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Table 4: Availability of evidence for each outcome measure with respect to 
measurement properties 
 
 
 Pain Grip TUG AIMS2 SEIQoL QoL 
Reliability       
Inter-rater Not 
applicable 
Not 
available 
Yes Not 
applicable 
Not 
available 
Yes 
Intra-rater Not 
applicable 
Yes Yes No Not 
available 
Not 
available 
Test-retest Yes Yes Not 
available 
Yes Not 
available 
Not 
available 
Internal 
Consistency 
Not 
available 
Not 
available 
Not 
applicable 
Yes Yes Yes 
Validity       
Content Yes Yes Not 
available 
Yes Not 
available 
Yes 
Construct No Not 
available 
Not 
available 
Yes Yes Yes 
Criterion-
related 
Yes Not 
available 
Yes Not 
available 
Not 
available 
Not 
available 
Sensitivity Yes Not 
available 
Not 
available 
Yes Not 
available 
Not 
available 
 
